Home » Briefs » Apotex v. Sanofi-Aventis


Econ One’s expert economists have experience across a wide variety of services including antitrust, class certification, damages, financial markets and securities, intellectual property, international arbitration, labor and employment, and valuation and financial analysis.


Econ One’s resources including blogs, cases, news, and more provide a collection of materials from Econ One’s experts.

Cases and Engagements

Get an Inside look at Economics with the experts.
Managing Director

Ph.D. in Economics, University of California, Los Angeles

M.A. in Economics, University of California, Los Angeles

B.S. in Economics, Santa Clara University

Econ One, President, 1997 – Present

Founded Econ One, 1997

Micronomics, Inc., President and CEO, 1994 – 1997

Micronomics, Inc., Executive Vice President, 1988 – 1997

Cofounded Micronomics, Inc., 1988

National Economic Research Associates, Inc. (Last position was Senior Vice President and member of the Board of Directors) 1980 – 1988

U.S. District Court

U.S. Bankruptcy Court

State Court

Federal Energy Regulatory Commission

Various state tax and regulatory commissions

Private arbitration

International Arbitration

Share this Article
September 25, 2015

Apotex v. Sanofi-Aventis

The parties entered into a written settlement agreement related to patent infringement litigation over a generic to the brand-name medication Plavix, a blood thinner.  Certain aspects of the settlement were subject to regulatory approval. Apotex alleged that the defendants made false statements to various regulators which prevented the approval of the contract and delayed the entry of Apotex’s generic Plavix.

Econ One was retained by counsel for Apotex in the case Apotex v. Sanofi-Aventis. Econ One expert Jeffrey Leitzinger calculated Apotex’s lost profits as a result of its delayed entry into the market. Dr. Leitzinger provided testimony both at deposition and at trial regarding Apotex’s lost profits.

Industries: Pharmaceutical

Latest Related Resources and Insights